Technical Analysis for IMMX - Immix Biopharma, Inc.

Grade Last Price % Change Price Change
D 1.83 -7.11% -0.14
IMMX closed down 7.11 percent on Friday, March 24, 2023, on 47 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Fell Below 20 DMA Bearish -7.11%
200 DMA Support Bullish -7.11%
Volume Surge Other -7.11%
Bollinger Band Squeeze Range Contraction -7.11%
Slingshot Bearish Bearish Swing Setup -14.49%
Crossed Above 20 DMA Bullish -14.49%
Crossed Above 200 DMA Bullish -14.49%
MACD Bullish Signal Line Cross Bullish -14.49%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 11 hours ago
Down 5% about 11 hours ago
Fell Below Previous Day's Low about 11 hours ago
200 DMA Resistance about 14 hours ago
10 DMA Resistance about 14 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. It is developing IMX-110 that is in Phase Ib/IIa clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. The company has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase Ib clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc. was incorporated in 2012 and is based in Los Angeles, California.

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Sarcoma Ulcerative Colitis Abdominal Pain Crohn's Disease Soft Tissue Sarcoma Beigene

Is IMMX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Mar 23 Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment P...
Mar 11 Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank
Mar 6 ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14
Feb 27 Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission
Feb 15 Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S.
Feb 9 Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting
Feb 7 Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer
Feb 5 EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In January: Where Do SPY, Tesla, Apple And Ford Rank?
Jan 13 Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
Jan 6 Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached
See more IMMX news...


Indicator Value
52 Week High 3.4499
52 Week Low 0.68
Average Volume 122,546
200-Day Moving Average 1.95
50-Day Moving Average 2.24
20-Day Moving Average 2.00
10-Day Moving Average 1.94
Average True Range 0.21
RSI 42.86
ADX 13.75
+DI 23.07
-DI 20.70
Chandelier Exit (Long, 3 ATRs) 1.75
Chandelier Exit (Short, 3 ATRs) 2.38
Upper Bollinger Bands 2.26
Lower Bollinger Band 1.74
Percent B (%b) 0.18
BandWidth 26.22
MACD Line -0.09
MACD Signal Line -0.10
MACD Histogram 0.0043
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.04
Resistance 3 (R3) 2.05 2.00 2.01
Resistance 2 (R2) 2.00 1.94 1.99 1.99
Resistance 1 (R1) 1.91 1.91 1.89 1.90 1.98
Pivot Point 1.86 1.86 1.84 1.85 1.86
Support 1 (S1) 1.77 1.80 1.74 1.76 1.68
Support 2 (S2) 1.72 1.77 1.71 1.67
Support 3 (S3) 1.63 1.72 1.65
Support 4 (S4) 1.62